Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Pomerantz MM"'
Autor:
Scelo, G, Purdue, MP, Brown, KM, Johansson, M, Wang, Z, Eckel-Passow, JE, Ye, Y, Hoffman, JN, Choi, J, Foll, M, Gaborieau, V, Machiela, MJ, Colli, LM, Li, P, Sampson, JN, Abedi-Ardekani, B, Besse, C, Blanche, H, Boland, A, Burdette, L, Charbrier, A, Durand, G, Le Calvez-Kelm, F, Prokhortchouk, E, Robinot, N, Skyrabin, KG, Wozniak, MB, Yeager, M, Basta-Jovanovich, G, Dzamic, Z, Foretova, L, Holcatova, I, Janout, V, Mates, D, Mukeriya, A, Rascu, S, Zaridze, D, Bencko, V, Cybulski, C, Fabianova, E, Jinga, V, Lissowska, J, Lubinski, J, Navratilova, M, Rudnai, P, Szeszenia-Dabrowska, N, Benhamou, S, Cancel-Tassin, G, Cussenot, O, Baglietto, L, Boeing, H, Khaw, K-T, Weiderpass, E, Ljungberg, B, Sitaram, RT, Bruinsma, F, Jordan, SJ, Severi, G, Winship, I, Hveem, K, Vatten, LJ, Fletcher, T, Koppova, K, Larsson, SC, Wolk, A, Banks, RE, Selby, PJ, Easton, DF, Pharoah, P, Andreotti, G, Beane Freeman, LE, Koutros, S, Albanes, D, Mannisto, S, Weinstein, S, Clark, PE, Edwards, TL, Lipworth, L, Gapstur, SM, Stevens, VL, Carol, H, Freedman, ML, Pomerantz, MM, Cho, E, Kraft, P, Preston, MA, Wilson, KM, Gaziano, JM, Sesso, HD, Black, A, Freedman, ND, Huang, WY, Anema, JG, Kahnoski, RJ, Lane, BR, Noyes, SL, Petillo, D, Teh, BT, Peters, U, White, E, Anderson, GL, Johnson, L, Luo, J, Buring, J, Lee, I-M, Chow, W-H, Moore, LE, Wood, C, Eisen, T, Henrion, M, Larkin, J, Barman, P, Leibovich, BC, Choueiri, TK, Lathrop, GM, Rothman, N, Deleuze, J-F, McKay, JD, Parker, AS, Wu, X, Houlston, RS, Brennan, P, Chanock, SJ
Previous genome-wide association studies (GWAS) have identified six risk loci for renal cell carcinoma (RCC). We conducted a meta-analysis of two new scans of 5,198 cases and 7,331 controls together with four existing scans, totalling 10,784 cases an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::a8880583624fc71de8b8122512580e45
https://eprints.whiterose.ac.uk/116006/13/ncomms15724.pdf
https://eprints.whiterose.ac.uk/116006/13/ncomms15724.pdf
Autor:
Stopsack KH; Massachusetts General Hospital, Boston, MA, United States., Vijai J; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Conry M; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Berchuck JE; Emory University, Atlanta, Georgia, United States., Kemel Y; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Vasselman SE; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Freeman DA; Dana-Farber/Harvard Cancer Center, Boston, MA, United States., Lee GM; Dana-Farber Cancer Institute, Boston, MA, United States., Mandelker D; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Solit DB; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Morris MJ; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Penney KL; Brigham and Women's Hospital/Harvard Medical School, Boston, MA, United States., Abida W; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Offit K; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Mucci LA; Harvard T.H. Chan School of Public Health, Boston, MA, United States., Kantoff PW; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Pomerantz MM; Dana-Farber Cancer Institute, Boston, United States.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 25. Date of Electronic Publication: 2024 Oct 25.
Autor:
Choudhury AD; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Kwak L; Dana-Farber Cancer Institute, Boston, Massachusetts., Cheung A; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Allaire KM; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Marquez J; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Yang DD; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Tripathi A; City of Hope Comprehensive Cancer Center, Duarte, California., Kilar JM; Dana-Farber Cancer Institute, Boston, Massachusetts., Flynn M; Dana-Farber Cancer Institute, Boston, Massachusetts., Maynard B; Deciphera Pharmaceuticals, Waltham, Massachusetts., Reichel R; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Pace AF; Dana-Farber Cancer Institute, Boston, Massachusetts., Chen BK; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Van Allen EM; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Kilbridge K; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Wei XX; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., McGregor BA; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Pomerantz MM; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Bhatt RS; Harvard Medical School, Boston, Massachusetts.; Beth-Israel Deaconess Medical Center, Boston, Massachusetts., Sweeney CJ; South Australian Immunogenomics Centre, University of Adelaide, Adelaide, Australia., Bubley GJ; Harvard Medical School, Boston, Massachusetts.; Beth-Israel Deaconess Medical Center, Boston, Massachusetts., Jacene HA; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Taplin ME; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Huang FW; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California., Harshman LC; Dana-Farber Cancer Institute, Boston, Massachusetts., Fong L; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2024 Jun 04; Vol. 12 (6), pp. 704-718.
Autor:
McKay RR; Department of Medicine, University of California San Diego, La Jolla, California, USA.; Department of Urology, University of California San Diego, La Jolla, California, USA., Xie W; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Yang X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Acosta A; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Rathkopf D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Laudone VP; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Bubley GJ; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Einstein DJ; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Chang P; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Wagner AA; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Kane CJ; Department of Urology, University of California San Diego, La Jolla, California, USA., Preston MA; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA., Kilbridge K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Chang SL; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA., Choudhury AD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Trinh QD; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA., Kibel AS; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA., Taplin ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Publikováno v:
Cancer [Cancer] 2024 May 01; Vol. 130 (9), pp. 1629-1641. Date of Electronic Publication: 2024 Jan 01.
Autor:
Chen N; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., McGrath CB; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Ericsson CI; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Vaselkiv JB; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Rencsok EM; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.; Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts., Stopsack KH; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Guard HE; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Autio KA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Rathkopf DE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Enting D; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom., Bitting RL; Durham VA Health Care System, Durham, North Carolina., Mateo J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Campus, Barcelona, Spain., Githiaka CW; Department of Surgery, University of Nairobi, Nairobi, Kenya., Chi KN; BC Cancer, Vancouver, British Columbia, Canada., Cheng HH; University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington., Davis ID; Monash University Faculty of Medicine, Melbourne, Australia.; Eastern Health, Melbourne, Australia., Anderson SG; The Glasgow-Caribbean Centre for Development Research and the Caribbean Institute of Health Research, The University of the West Indies, Bridgetown, Barbados.; African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania., Badal SAM; African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania.; The University of the West Indies Mona, Kingston, Jamaica., Bjartell A; Department of Urology, Skåne University Hospital, Malmö, Sweden., Russnes KM; Department of Oncology, Oslo University Hospital, Oslo, Norway., Heath EI; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Henegan JC; Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi., Hyslop T; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Esteban E; Department of Medical Oncology, Hospital Universitario Central of Asturias, ISPA, Oviedo, Spain., Omlin A; OnkoZentrum, Zurich, Switzerland., McDermott R; St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland., Fay AP; PUCRS School of Medicine, Hospital Nora Teixeira, Porto Alegre, Brazil., Popoola AA; University of Ilorin, Ilorin, Nigeria., Ragin C; African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania.; Fox Chase Cancer Center, Philadelphia, Pennsylvania., Nowak J; Cancer ABCs, Brooklyn, New York., Gerke T; Prostate Cancer Clinical Trials Consortium, New York, New York., Kantoff PW; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., George DJ; Durham VA Health Care System, Durham, North Carolina., Penney KL; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Mucci LA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Publikováno v:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2024 Mar 01; Vol. 33 (3), pp. 419-425.
Autor:
Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Davidsohn MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Sotudian S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Lakshminarayanan G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Diossy M; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., El Zarif T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Canniff J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Madueke I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Li R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Jiang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Taing L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Awad M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Chau CH; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Figg WD; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Greten TF; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hata AN; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ligon KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Lin N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Meador C; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Parsons HA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Rajan A; Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Thakuria M; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Long H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Szallasi Z; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.; Danish Cancer Institute, Copenhagen, Denmark.; Department of Bioinformatics and Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA. matthew_freedman@dfci.harvard.edu.
Publikováno v:
Nature medicine [Nat Med] 2024 Mar; Vol. 30 (3), pp. 907.
Autor:
Stone BV; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA.; Department of Urology, Massachusetts General Hospital, Boston, MA, USA., Labban M; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA., Beatrici E; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA., Filipas DK; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA., Frego N; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA., Qian ZJ; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA., Voleti SS; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA., Osman NY; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lipsitz SR; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA., Feldman AS; Department of Urology, Massachusetts General Hospital, Boston, MA, USA., Kibel AS; Division of Urological Surgery, Brigham and Women's Hospital, Boston, MA, USA., Cole AP; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA., Trinh QD; Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St., Boston, MA, 02115, USA. qtrinh@bwh.harvard.edu.
Publikováno v:
World journal of urology [World J Urol] 2024 Jan 20; Vol. 42 (1), pp. 54. Date of Electronic Publication: 2024 Jan 20.
Autor:
Rencsok EM; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts., Slopen N; Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., McManus HD; Duke Cancer Institute, Durham, North Carolina., Autio KA; Memorial Sloan Kettering Cancer Center, New York, New York., Morgans AK; Dana-Farber Cancer Institute, Boston, Massachusetts., McSwain L; Patient author, Durham, North Carolina., Barata P; Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana.; University Hospitals Seidman Cancer Center, Cleveland, Ohio., Cheng HH; Division of Medical Oncology, University of Washington, Seattle, Washington.; Fred Hutchinson Cancer Center, Seattle, Washington., Dreicer R; University of Virginia Cancer Center, Charlottesville, Virginia., Gerke T; Prostate Cancer Clinical Trials Consortium (PCCTC), New York, New York., Green R; Prostate Cancer Clinical Trials Consortium (PCCTC), New York, New York., Heath EI; Karmanos Cancer Institute, Detroit, Michigan., Howard LE; Duke Cancer Institute, Durham, North Carolina., McKay RR; Department of Oncology, University of California San Diego Moores Cancer Center, La Jolla, California., Nowak J; Patient author, Durham, North Carolina.; Cancer ABCs, Brooklyn, New York., Pileggi S; Prostate Cancer Clinical Trials Consortium (PCCTC), New York, New York., Pomerantz MM; Dana-Farber Cancer Institute, Boston, Massachusetts., Rathkopf DE; Memorial Sloan Kettering Cancer Center, New York, New York., Tagawa ST; Division of Hematology and Medical Oncology, Weill Cornell Medical Center, New York, New York., Whang YE; Department of Medicine, Division of Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina., Ragin C; Fox Chase Cancer Center, Philadelphia, Pennsylvania.; African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania., Odedina FT; Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.; Prostate Cancer Transatlantic Consortium (CaPTC), Jacksonville, Florida., Kantoff PW; Memorial Sloan Kettering Cancer Center, New York, New York.; Convergent Therapeutics, Cambridge, Massachusetts., Vinson J; Prostate Cancer Clinical Trials Consortium (PCCTC), New York, New York., Villanti P; Movember Foundation, Melbourne, Australia., Haneuse S; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Mucci LA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., George DJ; Duke Cancer Institute, Durham, North Carolina.
Publikováno v:
Cancer research communications [Cancer Res Commun] 2024 Jan 08; Vol. 4 (1), pp. 55-64.
Autor:
Linder S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Severson TM; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Mijn KJC; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Nevedomskaya E; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Siefert JC; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Stelloo S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Freedman ML; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA; Division of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Poel H; Division of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Jerónimo C; Cancer Biology and Epigenetics Group, Research Center of the Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal., Henrique R; Cancer Biology and Epigenetics Group, Research Center of the Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal., Bergman AM; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: a.bergman@nki.nl., Zwart W; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands. Electronic address: w.zwart@nki.nl.
Publikováno v:
European urology [Eur Urol] 2023 Nov; Vol. 84 (5), pp. 455-460. Date of Electronic Publication: 2023 Jun 02.
Autor:
Rana HQ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., Stopfer JE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., Weitz M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Kipnis L; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., Koeller DR; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., Culver S; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., Mercado J; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., Gelman RS; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Underhill-Blazey M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., McGregor BA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA., Sweeney CJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA., Petrucelli N; Karmanos Cancer Institute, Wayne State University, Detroit, MI., Kokenakes C; Karmanos Cancer Institute, Wayne State University, Detroit, MI., Pirzadeh-Miller S; University of Texas Southwestern Medical Center, Dallas, TX., Reys B; University of Texas Southwestern Medical Center, Dallas, TX., Frazier A; Karmanos Cancer Institute at McLaren Clarkston, Clarkston, MI., Knechtl A; Karmanos Cancer Institute at McLaren Clarkston, Clarkston, MI., Fateh S; Karmanos Cancer Institute at McLaren Clarkston, Clarkston, MI., Vatnick DR; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., Silver R; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA., Kilbridge KE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA., Pomerantz MM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA., Wei XX; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA., Choudhury AD; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA., Sonpavde GP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA., Kozyreva O; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Lathan C; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Horton C; Ambry Genetics, Aliso Viejo, CA., Dolinsky JS; Ambry Genetics, Aliso Viejo, CA., Heath EI; Karmanos Cancer Institute, Wayne State University, Detroit, MI., Ross TS; University of Texas Southwestern Medical Center, Dallas, TX., Courtney KD; University of Texas Southwestern Medical Center, Dallas, TX., Garber JE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA., Taplin ME; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.
Publikováno v:
JCO oncology practice [JCO Oncol Pract] 2023 Nov; Vol. 19 (11), pp. 1069-1079. Date of Electronic Publication: 2023 Sep 21.